Clopidogrel - Hanmi Pharmaceutical
Alternative Names: Clopidogrel napadisilate; Clopidogrel napadisilate monohydrate; PidogulLatest Information Update: 23 Dec 2021
At a glance
- Originator Hanmi Pharmaceutical
- Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
- Mechanism of Action Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Acute coronary syndromes; Myocardial infarction; Peripheral arterial disorders; Stroke
Most Recent Events
- 10 Jan 2012 Hanmi Pharmaceutical's Clopidogrel product is available for market licensing in European Union as of 10 Jan 2012. http://www.hanmipharm.com/eng/index.asp
- 10 Jan 2012 Registered for Acute coronary syndromes in Cyprus (PO)
- 10 Jan 2012 Registered for Acute coronary syndromes in Germany (PO)